Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 13Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Genitourinary 1Classical hematology 1Breast 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Cyclophosphamide 79fludarabine phosphate 75Busulfan 53Whole-Body Irradiation 51Mycophenolic Acid 50Cyclosporine 47Peripheral Blood Stem Cell Transplantation 46fludarabine 42Antilymphocyte Serum 37Melphalan 36Tacrolimus 35Filgrastim 30Cord Blood Stem Cell Transplantation 27Radiotherapy 23Methotrexate 22Cytarabine 22Methylprednisolone 19Granulocyte Colony-Stimulating Factor 18apixaban 17Thiotepa 17Dalteparin 13thymoglobulin 12Rivaroxaban 12Alemtuzumab 12eltrombopag 11ferric carboxymaltose 10Surveys and Questionnaires 10Etoposide 10Epoetin Alfa 10Cyclosporins 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × paricalcitol × Classical hematology × Clear all
NCT00064376 2018-01-29

Paricalcitol in Treating Patients With Myelodysplastic Syndrome

Cedars-Sinai Medical Center

Phase 2 Completed
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡